Inhibition of thyroid hormone inactivation for cancer treatment

PRINCIPAL INVESTIGATORS: 
Dr. Kostja Renko, 
Prof. Dr. Lutz Schomburg 
Charité

SUMMARY

An initial compound library screen led to a preliminary list of hormone modulators. The compound target reportedly plays a role in different cancer entities. During the SPARK funding period, drug candidates were characterized for specificity, potency and on-cell effects. Furthermore, in silico drug design was started to predict improved candidates. Experimental approaches to verify the reported beneficial effects in a cancer cell line completed the overall strategy. Future plans include strategic cooperation with oncology experts.

PROJECT ACHIEVEMENTS DURING & AFTER SPARK

- Verification and characterization of >50 compounds from an HTS approach
- Further testing of selected, specific candidates on intact cells
- Ongoing validation of candidates in cancer cell lines
- Plan of strategic cooperations with oncologists